Literature DB >> 19066839

[Impact of surgery for residual tumors after chemotherapy].

J Hess1, F vom Dorp, M Becker, H Rübben, C Börgermann.   

Abstract

Metastases are a feature not only of local tumor manifestation but also of systemic disease. Thus, the question arises regarding the extent to which local therapy contributes to a systemic state of disease. With renal cell carcinoma, resection of pulmonary metastases is a common operation. Other sites should be considered individually. Only a well-defined subset of patients with metastasized urothelial carcinoma benefit from the resection of their metastases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19066839     DOI: 10.1007/s00120-008-1756-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  19 in total

1.  Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer.

Authors:  H W Herr; S M Donat; D F Bajorin
Journal:  J Urol       Date:  2001-03       Impact factor: 7.450

2.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

3.  Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention.

Authors:  Y Kollender; J Bickels; W M Price; K L Kellar; J Chen; O Merimsky; I Meller; M M Malawer
Journal:  J Urol       Date:  2000-11       Impact factor: 7.450

4.  Rising incidence of renal cell cancer in the United States.

Authors:  W H Chow; S S Devesa; J L Warren; J F Fraumeni
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

5.  Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.

Authors:  N B Itano; M L Blute; B Spotts; H Zincke
Journal:  J Urol       Date:  2000-08       Impact factor: 7.450

Review 6.  Principles of nephrectomy for malignant disease.

Authors:  G H J Mickisch
Journal:  BJU Int       Date:  2002-03       Impact factor: 5.588

7.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

8.  Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy.

Authors:  M A Dimopoulos; L Finn; C J Logothetis
Journal:  J Urol       Date:  1994-03       Impact factor: 7.450

9.  Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?

Authors:  Paul Sweeney; Randall Millikan; Machelle Donat; Christopher G Wood; Arlene Siefker Radtke; Curtis A Pettaway; H Barton Grossman; Colin P N Dinney; David A Swanson; Louis L Pisters
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

10.  Outcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience.

Authors:  Thomas A Aloia; René Adam; Daniel Azoulay; Henri Bismuth; Denis Castaing
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.